DiaMedica Inc  

(Public, CVE:DMA)   Watch this stock  
Find more results for DMA
0.120
0.000 (0.00%)
May 26 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.04 - 0.80
Open     -
Vol / Avg. 0.00/56,292.00
Mkt cap 8.16M
P/E     -
Div/yield     -
EPS -0.09
Shares 68.03M
Beta 0.13
Inst. own     -
Mar 24, 2015
DiaMedica Inc at Biotechnology Industry Organization (BIO) Asia International Conference
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -765.26% -326.94%
Return on average equity - -
CDP Score - -

Address

1 Carlson Pkwy N Ste 124
MINNEAPOLIS, MN 55447-4453
United States - Map
+1-763-2700603 (Phone)
+1-763-7104456 (Fax)

Website links

Description

DiaMedica Inc. (DiaMedica) is a development-stage biopharmaceutical company engaged in the development of therapies for metabolic disorders, kidney dysfunction and orphan diseases. DiaMedica's lead compound, DM-199, is a recombinant human tissue kallikrein-1 protein, rhKLK-1, for the treatment of both Type I and Type II diabetes and their complications. DM-199 improves glucose control by increasing insulin sensitivity and glucose uptake, and to improve endothelial function by inducing vasodilationDM199 is evaluated in Phase 1 and Phase 2 clinical trials for assessment of safety, tolerability, pharmacokinetics and changes in diabetes markers. DiaMedica is also developing a monoclonal antibody, DM204, for the treatment of type 2 diabetes and associated complications, including hypertension. DM204 specifically target and modulate the bradykinin 2 receptor (B2R) and is in preclinical stage of development.

Officers and directors

Richard D. Pilnik Independent Chairman of the Board
Age: 56
Rick Pauls President, Chief Executive Officer, Director
John Savage Chief Financial Officer
David Gurvey Vice President - Finance
Mark Williams Ph.D. Vice President - Research
Edward Rady Senior Consultant - Licensing and Partnering
James T. Parsons Corporate Secretary
Michael Giuffre MD Independent Director
Dawson J. Reimer Independent Director
Age: 43
Thomas G. Wellner Independent Director
Age: 50